You are viewing the site in preview mode

Skip to main content
Fig. 3 | Clinical Proteomics

Fig. 3

From: Serum proteomics for the identification of biomarkers to flag predilection of COVID19 patients to various organ morbidities

Fig. 3

Volcano plots showing differentially expressed proteins between control and organ morbidity phenotypes in COVID19. (A) Control and Cardiovascular morbidity phenotype. (B) Control and Pulmonary morbidity phenotype. (C) Control and Renal morbidity phenotype. (D) Control and Gastrointestinal morbidity phenotype. (E) Control and Neurological morbidity phenotype. (F) Control and Hepatic morbidity phenotype. With respect to organ morbidity phenotypes, Red dots represent proteins with increased fold change (> 2); blue dots represent proteins with decreased fold change (< 0.5); and grey dots represent proteins with no significant change

Back to article page